Skip to main content
  • Research Article
  • Open access
  • Published:

Use of therapeutic caffeine in acute care postoperative and critical care settings: a scoping review



Caffeine is the most utilised psychoactive drug worldwide. However, caffeine withdrawal and the therapeutic use of caffeine in intensive care and in the perioperative period have not been well summarised. Our objective was to conduct a scoping review of caffeine withdrawal and use in the intensive care unit (ICU) and postoperative patients.


PubMed, Embase, CINAHL Complete, Scopus and Web of Science were systematically searched for studies investigating the effects of caffeine withdrawal or administration in ICU patients and in the perioperative period. Areas of recent systematic review such as pain or post-dural puncture headache were not included in this review. Studies were limited to adults.


Of 2268 articles screened, 26 were included and grouped into two themes of caffeine use in in the perioperative period and in the ICU. Caffeine withdrawal in the postoperative period increases the incidence of headache, which can be effectively treated prophylactically with perioperative caffeine. There were no studies investigating caffeine withdrawal or effect on sleep wake cycles, daytime somnolence, or delirium in the intensive care setting. Administration of caffeine results in faster emergence from sedation and anaesthesia, particularly in individuals who are at high risk of post-extubation complications. There has only been one study investigating caffeine administration to facilitate post-anaesthetic emergence in ICU. Caffeine administration appears to be safe in moderate doses in the perioperative period and in the intensive care setting.


Although caffeine is widely used, there is a paucity of studies investigating withdrawal or therapeutic effects in patients admitted to ICU and further novel studies are a priority.

Peer Review reports


Caffeine is the most widely used psychoactive drugs worldwide and has been used therapeutically in anaesthesia, critical care, and pain medicine [1]. Perioperatively, caffeine (≥ 100 mg) provides adjunctive pain relief effects when added to common analgesics [2], and is commonly used in the treatment of post-dural puncture headaches [3]. Postoperatively the use of caffeine after elective colorectal surgery has been recommended to reduce the incidence of postoperative ileus [2, 4]. Caffeine has been used in neonatal intensive care units (ICU) to treat apnoea related syndromes with no long-term adverse effects [5, 6]. However, its effects are less well defined in critically ill adults and therapeutic use must be considered in the context of whether patients are chronic users or not.

Caffeine is a derivates of methylxanthine that acts by inhibiting adenosine receptors and the downstream neurotransmitters (releases norepinephrine, dopamine, and serotonin in the brain, promoting lipolysis and can increase blood catecholamines [7,8,9]. In infants, caffeine and methylxanthine act on central and peripheral receptors that stimulate the medullary respiratory centre [10]. This has a range of physiologic, cognitive, and psychomotor effects and influences wakefulness and sleep [11,12,13]. Caffeine has a complex relationship with endothelial cell function, in which it can cause vasodilation by increased intracellular calcium increasing nitric oxide, or vasoconstriction mediated by adenosine antagonism. The effects on the cardiovascular system are seen by mild changes to heart rate and blood pressure, with no consensus in the literature that increased caffeine consumption will increase risk of arrhythmias [14,15,16,17]. Abrupt cessation of caffeine in chronic users, such as with fasted patients postoperatively, will affect 10–55% of individuals and may have adverse effects such as increased cerebral blood flow velocity, quantitative electroencephalogram changes and symptoms including headache, drowsiness, decreased alertness, flu like symptoms, nausea/vomiting, and myalgias [18, 19]. Its potential uses to treat withdrawal symptoms, to moderate disturbed sleep-wake cycles, and reduce ICU/postoperative delirium have not been systematically reviewed. Our objective was to conduct a scoping review surrounding the use of caffeine in acute care postoperative and critical care settings in order to summarize the available published evidence and to identify future research priorities.


Data sources

PubMed, Embase, CINAHL Complete, Scopus and Web of Science were searched using the Medical Subject Headings (MeSH) and key words on 1st May 2020 (see Additional file 1: Appendix).

Study questions

  1. 1.

    What is the evidence for caffeine in the ICU and what is the evidence for caffeine perioperatively?

    1. a.

      Caffeine withdrawal and administration on the development of postoperative headache or delirium

    2. b.

      Caffeine withdrawal and administration on induction and emergence from sedation

    3. c.

      Safety and changes associated with caffeine administration

Inclusion criteria

Studies of any methodology were included if they investigated the effect or safety of caffeine or caffeine-containing products on hospitalised patients, with a focus on perioperative patients and those admitted to the ICU.

Exclusion criteria

Studies were excluded if they specifically evaluated post-dural puncture headaches, caffeine as a pain adjunct, effect on ileus or gastrointestinal motility, the risk of arrhythmias from habitual caffeine intake, effects during pregnancy, or were community-based. Studies were also excluded if they investigated the effect of caffeine outside of the intensive care or postoperative hospital setting. Studies that reported on caffeine overdose in the community were not included. Studies were excluded if they reported on individuals under 18 years of age. Animal studies, review articles and editorials that did not contain novel information were excluded.

Study protocol

The review methodology was conducted according to the Joanna Briggs Institute [20]. Study selection was performed independently by two physician reviewers (MB, VR) at each stage 1 (title and abstract) and stage 2 (full text screening). Any discrepancy was solved by a discussion between the two reviewers and if needed a third reviewer (KL) was available to make the final decision.

Once all articles for inclusion were screened, data was extracted by one of the authors (MB) using the data extraction table. When any information included in a study was unclear, the authors were contacted to provide clarification or further details.


Analysis was primarily descriptive. Given the heterogeneity of the study questions and designs, a quantitative mathematical summary statistic was not calculated. Individual results were summarized where appropriate.


Literature search

We identified 4059 articles, of which 1791 were duplicates. Of the remaining 2268 unique articles, 1305 were excluded based on their titles and abstracts (Fig. 1). Following full text review of the remaining 963 articles, a further 938 were excluded. The references of the remaining 25 articles were hand-searched for additional publications and one further relevant study was found. The results of the 26 studies are summarized in Table 1.

Fig. 1
figure 1

PRISMA flow diagram of article selection

Table 1 Summary of extraction articles


The 26 articles retrieved were grouped into themes of caffeine in the ICU [21,22,23,24] and caffeine in the perioperative setting [25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46]. These were further subdivided into withdrawal headaches or delirium, effect on induction and emergence from sedation and safety/changes associated with caffeine administration. This included 3 case reports [32, 41, 42], 14 studies with 1–199 participants [2224, 28, 33, 3640, 4346], seven studies with 200–500 participants [25,26,27, 29,30,31, 34], one with 500–1000 participants [35] and one study that surveyed 25 intensive care units across 17 institutions [21].

Caffeine use in the intensive care unit

There were four studies investigating the use of caffeine in the intensive care unit, including a national survey and three studies which administered caffeine to ICU patients [21,22,23,24]. Dzerba et al performed a national survey of 25 ICUs across 17 institutions in the United States of America to evaluate the delirium screening tools and protocols in place to reduce the incidence of delirium. Afternoon caffeine minimisation was utilised in 32% of ICUs to reduce delirium and improve sleep [21].

One study investigated caffeine administration on induction or emergence from sedation in the ICU. Sadat et al randomised 80 mechanically ventilated ICU patients to either receive 3.5 g of coffee in 100 mL of water or placebo (100 mL of distilled water) at 10 am in the morning [22]. The dose of caffeine administered in this study was unknown. There was a significant increase in spontaneous respiratory rate and tidal volumes at 30 and 60 min in patients who received coffee compared to placebo [22].

Two studies investigated other effects of caffeine. The first study found concomitant administration of quinolones and caffeine in 12 ICU patients could inhibit the metabolism of caffeine resulting in higher plasma levels [23]. The second study was a randomised controlled trial that administered 3 mg/kg caffeine to assess liver function in 33 ICU patients with impaired liver function and 40 with normal liver function [24]. Individuals with impaired liver function had significantly longer elimination of caffeine compared to those with normal liver function. Neither study reported on any adverse events of caffeine administration [23, 24].

Caffeine use in the perioperative period

There were 22 studies investigating caffeine use in the perioperative period [25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45]. There were 10 studies investigating the effect of caffeine perioperatively and the development of postoperative headache [25,26,27,28,29,30,31,32,33,34]. Seven investigated caffeine withdrawal [25,26,27,28,29,30,31,32,33,34] and three studies administered oral caffeine to prevent postoperative headache [32,33,34]. Of the seven prospective studies investigating the effect of caffeine withdrawal, five studies found caffeine withdrawal increased the incidence of postoperative headache [25,26,27,28,29,30,31,32,33,34]. Three studies investigated the administration of caffeine to relieve postoperative headache [32,33,34]. There was one case report of the successful administration of caffeine and ergometrine to relieve a postoperative headache [32]. There were two prospective randomised controlled trials which found prophylactic caffeine administration decreased the incidence of postoperative headache [33, 34].

Eight studies investigated induction and emergence from anaesthesia [39,40,41,42,43,44,45]. Individuals who had a high caffeine intake required less propofol for induction [39, 40], but greater opioids for induction for cardiac surgery [46] and lower cognitive scores postoperatively [46]. Furthermore, five studies found the administration of intravenous (IV) caffeine enhanced emergence from anaesthesia [41,42,43,44,45]. Two case reports used IV caffeine to enhance emergence from sedation. The first study in a 52-year old male who received 500 mg IV caffeine to facilitate intraoperative language mapping who was slow to emerge after anaesthesia was ceased [41]. The second case study was a 16-year old male who underwent a dental procedure using sevoflurane anaesthesia who experienced ongoing hypopnea and desaturation up to 90 min after the procedure. Caffeine was used (60 mg or 0.8 mg/kg) and resulted in increased alertness, no further desaturation, increased respiratory rate and tidal volumes [42]. Gouda et al. randomised 60 patients undergoing uvulopalatopharyngoplasty for treatment for obstructive sleep apnoea to either receive 500 mg IV caffeine or saline [45]. Individuals who received caffeine had significantly faster time to extubation and fewer post-extubation respiratory complications (supraglottic obstruction, laryngospasm, reintubation, breath holding, desaturation) [45]. Similar results were demonstrated by Fong et al., who randomised eight patients to receive IV caffeine at 7.5 mg/kg or saline and demonstrated caffeine resulted in significantly faster emergence from isoflurane anaesthesia [43]. This study reported no adverse outcomes from administration of caffeine [43]. Warner et al. performed a retrospective audit of caffeine administration (median dose of 150 mg) in the post-anaesthetic recovery area to increase alertness in 151 heavily sedated patients [44]. There was a significant improvement in sedation scores with no change in respiratory or cardiac outcomes and no reported adverse events [44].

There were four studies that investigated the safety and changes associated with caffeine administration [35,36,37,38]. Intraoperative or postoperative caffeine may increase the incidence of postoperative nausea/vomiting [37, 38]. Intraoperative caffeine was found not to affect the incidence of postoperative atrial fibrillation [38] and reduce time to spontaneous voiding post indwelling bladder catheter removal postoperatively [36]. A national survey of 882 nurses found that 85% still practised caffeine restriction in patients after an acute myocardial infarction [35].


In this review we systematically identified only 26 studies that examine caffeine therapeutic use and/or withdrawal in the ICU and perioperative settings. Furthermore, only four studies investigating the use of caffeine in the intensive care unit. This is somewhat surprising considering that withdrawal from caffeine in other settings has been extensively described in the literature for almost 200 years and as an official diagnosis in ICD-10 by the World Health Organisation [19, 47, 48]. Furthermore, given the commonality of use of caffeine products and its broad range of psychoactive and physiologic effects, it may be expected to have significant applications in critical care and perioperative medicine. Despite this, there is a paucity of clinical studies investigating withdrawal or administration of caffeine in the intensive care setting, and use of caffeine to facilitate emergence from anaesthesia or use in the perioperative period.

Onset of caffeine withdrawal occurs as early as 12–24 h post abstinence, with symptoms lasting between 2 to 9 days [19]. It is unsurprising that when chronic caffeine users are admitted to hospital and are required to fast for surgery, they develop a caffeine withdrawal headache postoperatively. Administration of caffeine perioperatively can reduce the incidence of postoperative headache due to caffeine withdrawal. In the intensive care setting, these patients are also likely withdrawing from caffeine. While there is routine screening and management for alcohol or smoking, caffeine consumption or withdrawal is not routinely documented. Currently, there are no studies investigating caffeine withdrawal in the intensive care setting. Although the typical effects of caffeine may not be seen, the effect on circadian rhythm, cognition and mood may be impaired which may contribute to delirium. Caffeine minimisation is one strategy used both in the community and the intensive care setting to reduce the incidence of delirium [21, 49]. In the community, current strategies to reduce delirium include caffeine minimisation after midday. One pilot study across 21 nursing homes and one dementia special care unit found eliminating caffeine intake in the afternoon and evening resulted in significant improvement in sleep scores but no change in agitation/aggression, irritability and aberrant motor behaviour [49]. However, administration of caffeine earlier in the day may help reset and normalise circadian rhythm [50, 51].

Caffeine can facilitate emergence from sedation or anaesthesia. In the intensive care setting, administration of caffeine has been shown to increase spontaneous breathing in intubated patients, which may help wean patients from mechanical ventilation [22]. Postoperatively, caffeine has been used to facilitate emergence from anaesthesia [41,42,43,44]. Administration of caffeine to reduce time to emergence from anaesthesia has been demonstrated in animal studies [43, 52, 53]. Increasing emergence from anaesthesia to assist with respiratory drive and return of upper airway tone would be helpful in high risk patients, such as the morbidly obese, individuals with severe obstructive sleep apnoea, or those who are more susceptible to opioid medications with respiratory depression effects. A similar process may occur in adults emerging from anaesthesia that has been suggested in infants, in which caffeine acts centrally on the medullary respiratory centre to increase sensitivity to carbon dioxide demonstrated in infants [10] and may offset the effects from opioids and other sedative medications. The use of caffeine and its derivatives are not routinely used nor are they licensed for the use to facilitate emergence from anaesthesia in adults. Due to the small number of studies included, that used a wide range of caffeine dosing (60 mg to 500 mg), it is unclear what dose will be effective to facilitate emergence from anaesthesia. There is growing interest in the effects of caffeine habits on induction of anaesthesia and in the use of caffeine to increase recovery and emergence from anaesthesia. Individuals with high caffeine intake (> 3 cups/day) may require lower doses of induction agents (including opiates and sedative agents such as propofol), which is thought to be due to caffeine dependence and withdrawal resulting in lower arousal preoperatively [39, 40] . Additionally, individuals with high caffeine intake were shown to have worse cognitive functioning post-anaesthesia, likely from caffeine dependence [46]. None of the studies included administered preoperative caffeine or investigated the risk of awareness with caffeine administration. In non-anaesthetised inviduals who are at rest, the administration of caffeine (3 mg/kg or average of 181 mg) in one small study was found to decrease the proportion of slow delta or theta wave activity as measured by electroencephalogram (EEG) [54]. The effect of 200 mg of caffeine versus placebo on the EEG theta/delta ratio will be further investigated by a randomised, double-blinded clinical trial protocol published in 2016 [55]. No studies to date have investigated the effect of caffeine on the EEG readings in an anaesthetised individual. As caffeine is a central nervous system stimulant, there is a risk that early administration of caffeine could increase awareness during anaesthesia. The use of caffeine in the ICU setting has the benefit of reducing excessive daytime somnolence and removing barriers to participate in daytime physiotherapy.

The secondary beneficial effects of caffeine administration could be exploited in the ICU setting. Gastrointestinal dysmotility is a common problem in the intensive care patients, compounded by opiates, surgery, sepsis and electrolyte abnormalities [56]. Caffeine has been shown to effectively improve gastrointestinal motility with no significant side effect [57]. Historically, caffeine intake has been limited in the perioperative period due to the risk of vasospasm and risk of cardiac events [58, 59] . However, caffeine use after an acute myocardial infarct may be reduce the risk of cardiovascular mortality [60, 61] and does not increase the risk of atrial fibrillation after cardiac surgery [38]. At rest, caffeine appears to promote generalised vasodilation and does not affect digital microvascular perfusion [62, 63], however it does result in reduced cerebral blood flow [64, 65]. Additionally, there are psychological benefits due to the socio-cultural aspects associated with coffee and caffeine [66]. Future studies investigating the use of caffeine in the ICU setting should be aware of these secondary effects particular in patients who have undergone neurological or plastic reconstructive procedures or have had a recent stroke. Additionally, future studies need to consider the significant interindividual variability with respect to caffeine metabolism by CYP 450 1A1/2 that resulting in a halflife from 3 to 10 h [7, 67]. This may also explain the large variations in daily caffeine intake and differences in pharmacodynamics present in the population. These differences may be more pronounced in individuals who have a high caffeine intake.

As a scoping review, the major limitation is the inability to perform systematic analysis between groups due to the heterogeneity of papers and themes found. Advantages of this review include no language limitation, inclusion of grey research (i.e. conference abstracts) and a thorough search using a comprehensive search strategy designed with the assistance of an expert medical librarian.


In conclusion, we identified some areas of caffeine use but this is largely an under investigated area. Caffeine withdrawal due to hospitalisation occurs rapidly and patients can develop withdrawal symptoms including headache. Administration of caffeine or coffee supplementation has been shown to be safe, can result in faster emergence from anaesthesia. This scoping review has highlighted gaps in the literature regarding the use of caffeine in the intensive care unit and in the perioperative period. Studies examining mitigation of withdrawal effects of caffeine use, optimal dosing, preferred route of administration (i.e. parenteral versus oral) and therapeutic use of caffeine as adjunctive therapies for pain management and delirium are a priority.

Availability of data and materials

Not applicable.



Intensive Care Unit




  1. Temple JL, Bernard C, Lipshultz SE, Czachor JD, Westphal JA, Mestre MA. The safety of ingested caffeine: a comprehensive review. Front Psychiatry. 2017;8:80.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Derry CJ, Derry S, Moore RA. Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Database Syst Rev 2014;(12):CD009281.

  3. Basurto Ona X, Osorio D, Bonfill Cosp X. Drug therapy for treating post-dural puncture headache. Cochrane Database Syst Rev 2015;(7):CD007887.

  4. Gustafsson UO, Scott MJ, Hubner M, Nygren J, Demartines N, Francis N, et al. Guidelines for perioperative Care in Elective Colorectal Surgery: enhanced recovery after surgery (ERAS((R))) society recommendations: 2018. World J Surg. 2019;43(3):659–95.

  5. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112–21.

    Article  CAS  PubMed  Google Scholar 

  6. Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357(19):1893–902.

    Article  CAS  PubMed  Google Scholar 

  7. Benowitz NL. Clinical pharmacology of caffeine. Annu Rev Med. 1990;41(1):277–88.

    Article  CAS  PubMed  Google Scholar 

  8. Daly JW, Shi D, Nikodijevic O, Jacobson KA. The role of adenosine receptors in the central action of caffeine. Pharmacopsychoecologia. 1994;7(2):201–13.

    PubMed  PubMed Central  Google Scholar 

  9. Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev. 1992;17(2):139–70.

    Article  CAS  PubMed  Google Scholar 

  10. Dobson NR, Hunt CE. Pharmacology review: caffeine use in neonates: indications, pharmacokinetics, clinical effects. NeoReviews. 2013;14(11):e540–50.

    Article  Google Scholar 

  11. Kamimori GH, McLellan TM, Tate CM, Voss DM, Niro P, Lieberman HR. Caffeine improves reaction time, vigilance and logical reasoning during extended periods with restricted opportunities for sleep. Psychopharmacology. 2015;232(12):2031–42.

    Article  CAS  PubMed  Google Scholar 

  12. McLellan TM, Caldwell JA, Lieberman HR. A review of caffeine's effects on cognitive, physical and occupational performance. Neurosci Biobehav Rev. 2016;71:294–312.

    Article  CAS  PubMed  Google Scholar 

  13. Clark I, Landolt HP. Coffee, caffeine, and sleep: a systematic review of epidemiological studies and randomized controlled trials. Sleep Med Rev. 2017;31:70–8.

    Article  PubMed  Google Scholar 

  14. Graboys TB, Blatt CM, Lown B. The effect of caffeine on ventricular ectopic activity in patients with malignant ventricular arrhythmia. Arch Intern Med. 1989;149(3):637–9.

    Article  CAS  PubMed  Google Scholar 

  15. Pelchovitz DJ, Goldberger JJ. Caffeine and cardiac arrhythmias: a review of the evidence. Am J Med. 2011;124(4):284–9.

    Article  CAS  PubMed  Google Scholar 

  16. Abdelfattah R, Kamran H, Lazar J, Kassotis J. Does caffeine consumption increase the risk of new-onset atrial fibrillation? Cardiology. 2018;140(2):106–14.

    Article  CAS  PubMed  Google Scholar 

  17. Cheng M, Hu Z, Lu X, Huang J, Gu D. Caffeine intake and atrial fibrillation incidence: dose response meta-analysis of prospective cohort studies. Can J Cardiol. 2014;30(4):448–54.

    Article  CAS  PubMed  Google Scholar 

  18. Jones HE, Herning RI, Cadet JL, Griffiths RR. Caffeine withdrawal increases cerebral blood flow velocity and alters quantitative electroencephalography (EEG) activity. Psychopharmacology. 2000;147(4):371–7.

    Article  CAS  PubMed  Google Scholar 

  19. Juliano LM, Griffiths RR. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology. 2004;176(1):1–29.

    Article  CAS  PubMed  Google Scholar 

  20. Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13(3):141–6.

    Article  PubMed  Google Scholar 

  21. Dzierba A, Smithburger P, Devlin J, Swan J, Kane-Gill S. A national evaluation of ICU delirium identification, prevention and treatment practices. Crit Care Med. 2015;43(12):148.

    Article  Google Scholar 

  22. Sadat Z, Salehi N, Afazel MR, Aboutalebi MS, Dianati M. The effect of espresso coffee consumption through gastric tube on respiratory indicators among mechanically ventilated patients: a randomized clinical trial. HAYAT. 2017;23(2):185–95.

    Google Scholar 

  23. Staib AH, Stille W, Dietlein G, Shah PM, Harder S, Mieke S, et al. Interaction between quinolones and caffeine. Drugs. 1987;34(Suppl 1):170–4.

  24. Calatayud O, Rodriguez M, Sánchez-Alcrazt A, Ibánez P. Caffeine test assessment for measuring liver function in critically ill patients. Article. J Clin Pharm Ther. 1995;20(1):23–9.

    Article  CAS  PubMed  Google Scholar 

  25. Matsota PK, Christodoulopoulou TC, Batistaki CZ, Arvaniti CC, Voumvourakis KI, Kostopanagiotou GG. Factors associated with the presence of postoperative headache in elective surgery patients: a prospective single center cohort study. J Anesth. 2017;31(2):225–36.

    Article  PubMed  Google Scholar 

  26. Nikolajsen L, Larsen KM, Kierkegaard O. Effect of previous frequency of headache, duration of fasting and caffeine abstinence on perioperative headache. Br J Anaesth. 1994;72(3):295–7.

    Article  CAS  PubMed  Google Scholar 

  27. Gill PS, Guest C, Rabey PG, Buggy DJ. Perioperative headache and day case surgery. Eur J Anaesthesiol. 2003;20(5):401–3.

    Article  CAS  PubMed  Google Scholar 

  28. Galletly DC, Fennelly M, Whitwam JG. Does caffeine withdrawal contribute to postanaesthetic morbidity? Lancet. 1989;1(8650):1335.

    Article  CAS  PubMed  Google Scholar 

  29. Verhoeff FH, Millar JM. Does caffeine contribute to postoperative morbidity? Lancet. 1990;336(8715):632.

    Article  CAS  PubMed  Google Scholar 

  30. Fennelly M, Galletly DC, Purdie GI. Is caffeine withdrawal the mechanism of postoperative headache? Anesth Analg. 1991;72(4):449–53.

    Article  CAS  PubMed  Google Scholar 

  31. Weber JG, Ereth MH, Danielson DR. Perioperative ingestion of caffeine and postoperative headache. Mayo Clin Proc. 1993;68(9):842–5.

    Article  CAS  PubMed  Google Scholar 

  32. Hampl KF, Stotz G, Schneider MC. Postoperative transient hemihypaesthesia and severe headache associated with caffeine withdrawal [7]. Anaesthesia. 1994;49(3):266–7.

    Article  CAS  PubMed  Google Scholar 

  33. Hampl KF, Schneider MC, Rüttimann U, Ummenhofer W, Drewe J. Perioperative administration of caffeine tablets for prevention of postoperative headaches. Can J Anaesth. 1995;42(9):789–92.

    Article  CAS  PubMed  Google Scholar 

  34. Weber JG, Klindworth JT, Arnold JJ, Danielson DR, Ereth MH. Prophylactic intravenous administration of caffeine and recovery after ambulatory surgical procedures. Mayo Clin Proc. 1997;72(7):621–6.

    Article  CAS  PubMed  Google Scholar 

  35. Riegel B, Thomason T, Carlson B, Gocka I. Are nurses still practicing coronary precautions? A national survey of nursing care of acute myocardial infarction patients. Am J Crit Care. 1996;5(2):91–8.

    Article  CAS  PubMed  Google Scholar 

  36. Leach D, Spaulding J, Thomas J, Conn C, Kutash M. The effect of caffeine on postoperative urinary retention after joint replacement surgery. Orthop Nurs. 2013;32(5):282–5.

    Article  PubMed  Google Scholar 

  37. Steinbrook RA, Garfield F, Batista SH, Urman RD. Caffeine for the prevention of postoperative nausea and vomiting. J Anaesthesiol Clin Pharmacol. 2013;29(4):526–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Lagier D, Nee L, Guieu R, Kerbaul F, Fenouillet E, Roux N, et al. Peri-operative oral caffeine does not prevent postoperative atrial fibrillation after heart valve surgery with cardiopulmonary bypass: a randomised controlled clinical trial. Eur J Anaesthesiol. 2018;35(12):911–8.

  39. O'Connor S, Maese S, Vizcaychipi M. High daily caffeine intake prior to surgery is associated with lower propofol requirements for anaesthetic induction. Brit J Anaesthesia. 2019;123(4):e497–8.

    Article  Google Scholar 

  40. Stanley TH, de Lange S. The effect of population habits on side effects and narcotic requirements during high-dose fentanyl anaesthesia. Can Anaesth Soc J. 1984;31(4):368–76.

    Article  CAS  PubMed  Google Scholar 

  41. Schrader L, Horsfall J, Bookheimer S. Use of caffeine during intraoperative awake languagemapping. J Clin Neurophysiol. 2011;28(4):424–9.

    Article  Google Scholar 

  42. Evans M, Lam H, Austin T. Intravenous caffeine Rescue for Postoperative Hypoventilation in a 16-year-old with trisomy 10: a case report. Article A and A Case Reports. 2017;9(2):50–1.

    Article  PubMed  Google Scholar 

  43. Fong R, Wang L, Zacny JP, Khokhar S, Apfelbaum JL, Fox AP, et al. Caffeine accelerates emergence from Isoflurane anesthesia in humans: a randomized, double-blind, Crossover Study. Anesthesiol. 2018;129(5):912–20.

  44. Warner NS, Warner MA, Schroeder DR, Sprung J, Weingarten TN. Effects of caffeine administration on sedation and respiratory parameters in patients recovering from anesthesia. Bosn J Basic Med Sci. 2018;18(1):101–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Gouda N. Intravenous Caffeine for Adult Patients with Obstructive Sleep Apnea Undergoing Uvulopalatopharyngoplasty: Effects on Postoperative Respiratory Complications and Recovery Profile Med J Cairo Univ 2010;78:155–159.

  46. Flatt JR, Birrell PC, Hobbes A. Effects of anaesthesia on some aspects of mental functioning of surgical patients. Anaesth Intensive Care. 1984;12(4):315–24.

    Article  CAS  PubMed  Google Scholar 

  47. Lane JD. Effects of brief caffeinated-beverage deprivation on mood, symptoms, and psychomotor performance. Pharmacol Biochem Behav. 1997;58(1):203–8.

    Article  CAS  PubMed  Google Scholar 

  48. American Psyciatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM–5). Available at: Accessed 9 Mar 2021.

  49. de Pooter-Stijnman LMM, Vrijkotte S, Smalbrugge M. Effect of caffeine on sleep and behaviour in nursing home residents with dementia. Eur Geriatr Med. 2018;9(6):829–35.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Smith T, Farr L, Langenbergpanzer S, Petersen M. The effects of caffeine ingestion on restoration of circadian rhythmicity posteratively in the laboratory rat. Aviat Space Environ Med. 1985;56(5):500–0.

  51. Burke TM, Markwald RR, McHill AW, et al. Effects of caffeine on the human circadian clock in vivo and in vitro. Sci Transl Med. 2015;7(305):305ra146.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Wang Q, Fong R, Mason P, Fox AP, Xie Z. Caffeine accelerates recovery from general anesthesia. J Neurophysiol. 2014;111(6):1331–40.

    Article  CAS  PubMed  Google Scholar 

  53. Fong R, Khokhar S, Chowdhury AN, et al. Caffeine accelerates recovery from general anesthesia via multiple pathways. J Neurophysiol. 2017;118(3):1591–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Jung JY, Lee H-W, Jang I-S, Suk K, Lee M-G. Caffeine Maintains Arousal Level and Prevents Change of Electroencephalogram Spectral Powers with Time at Rest. J Korean Sleep Res Soc. 2014;11(1):5–10.

    Article  Google Scholar 

  55. Putman P. Effects of Caffeine on EEG Theta/Beta Ratio and Cognitive Control. Identifier: NCT02940808.

  56. Vazquez-Sandoval A, Ghamande S, Surani S. Critically ill patients and gut motility: Are we addressing it? World J Gastrointest Pharmacol Ther. 2017;8(3):174–9.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Gkegkes ID, Minis EE, Iavazzo C. Effect of caffeine intake on postoperative ileus: a systematic review and meta-analysis. Dig Surg. 2020;37(1):22–31.

    Article  PubMed  Google Scholar 

  58. Dinman S, Giovannone MK. The care and feeding of microvascular flaps: how nurses can help prevent flap loss. Plast Surg Nurs. 1994;14(3):154–64.

    Article  CAS  PubMed  Google Scholar 

  59. Kirin I, Franković KJ, Kovačević M, Martinović G, Primc D. An overview of replantation and transplantation of the upper extremity. Review Medicina Fluminensis. 2012;48(1):15–22.

    Google Scholar 

  60. van Dongen LH, Molenberg FJ, Soedamah-Muthu SS, Kromhout D, Geleijnse JM. Coffee consumption after myocardial infarction and risk of cardiovascular mortality: a prospective analysis in the alpha omega cohort. Am J Clin Nutr. 2017;106(4):1113–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Silletta MG, Marfisi R, Levantesi G, et al. Coffee consumption and risk of cardiovascular events after acute myocardial infarction: results from the GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico)-Prevenzione trial. Circulation. 2007;116(25):2944–51.

    Article  CAS  PubMed  Google Scholar 

  62. Barton B, Kleinert JM. The effect of caffeine on digital haemodynamics. J Hand Surg Br. 1994;19(3):301–2.

    Article  CAS  PubMed  Google Scholar 

  63. Knight R, Pagkalos J, Timmons C, Jose R. Caffeine consumption does not have an effect on digital microvascular perfusion assessed by laser Doppler imaging on healthy volunteers: a pilot study. J Hand Surg Eur Vol. 2015;40(4):412–5.

    Article  CAS  PubMed  Google Scholar 

  64. Addicott MA, Yang LL, Peiffer AM, Burnett LR, Burdette JH, Chen MY, et al. The effect of daily caffeine use on cerebral blood flow: how much caffeine can we tolerate? Hum Brain Mapp. 2009;30(10):3102–14.

  65. Sumpio BE, Riley JT, Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol. 2002;34(12):1508–12.

    Article  CAS  PubMed  Google Scholar 

  66. Rispoli M, Bevilacqua A, De Falco G, Esposito D, Matrullo S. Preanesthesia premedication: the “Monaldi” protocol. Anesthesiology. 2018;129(4):853–4.

    Article  Google Scholar 

  67. Blanchard J, Sawers SJ. Comparative pharmacokinetics of caffeine in young and elderly men. J Pharmacokinet Biopharm. 1983;11(2):109–26.

    Article  CAS  PubMed  Google Scholar 

Download references


We thank Ms. Natalie Barker for her valuable assistance with the systematic search.


Nil sources of funding. There was no funding body involved in the study and collection, analysis, and interpretation of data or in writing of the manuscript.

Author information

Authors and Affiliations



KBL conceived the study. MB and KBL designed the protocol. MB and VR jointly investigated, analysed, and interpreted the articles. MB drafted the primary manuscript. Additional writing, review and editing was provided by all authors. All authors read and approved the final manuscript. All authors agree to be personally accountable for their own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Corresponding author

Correspondence to K. B. Laupland.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bright, M., Raman, V. & Laupland, K.B. Use of therapeutic caffeine in acute care postoperative and critical care settings: a scoping review. BMC Anesthesiol 21, 100 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: